The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is giving three clinical trial centers a $125,000 incentive to increase accessibility and volunteer enrollment in Parkinson’s disease (PD) studies as part of its new Parkinson’s Disease Trial Recruitment Innovation (PD-TRI) program. The centers – Barrow Neurological Institute in…
Living Cell Technologies (LCT) has completed treatment in the six patients enrolled in the third and final cohort of the Phase 2b clinical trial evaluating NTCELL in the treatment of Parkinson’s disease (PD) at Auckland City Hospital in New Zealand. LCT’s lead product, NTCELL, is an alginate-coated capsule…
Klick Labs has developed a device that records and transmits Parkinson’s Disease tremors so doctors get a sense of what a patient goes through in real time. By showing what a patient experiences, the hope is that the SymPulse Tele-Empathy Device prompts doctors to pay even more attention to patients’ needs,…
Acorda Therapeutics, which recently announced a corporate restructuring, will focus on the late-stage development of its two therapies for Parkinson’s disease, CVT-301 and tozadenant. The news comes after a March 31 ruling by the U.S. District Court in Wilmington, Delaware, invalidated four Acorda patents related to multiple sclerosis therapy Ampyra. Acorda, based in…
American scientists have formed what they call the BRAIN Center to develop, test and market innovative technologies to help people with neurological diseases such as Parkinson’s, stroke and paralysis, and people who have lost limbs. The goal of BRAIN, which stands for Building Reliable Advances and Innovation in Neurotechnology, is to…
The fourth and last patient of the first group in a clinical trial of stem cell transplants in Parkinson’s disease has successfully received the transplant, the International Stem Cell Corporation (ISCO) reported. Researchers are now preparing for the next stage, in which patients will receive a higher number of…
The latest result from Voyager Therapeutic’s Phase 1 clinical trial on gene therapy (VY-AADC01) for advanced Parkinson’s disease shows early promise for the improvement of motor functions and quality of life of patients. These data were presented as part of an emerging oral presentation session at the 2017 Annual Meeting…
Impax Laboratories is presenting data on its approved Parkinson’s disease treatment, Rytary, as well as findings in a clinical trial assessing a version of this extended-release carbidopa and levodopa mixture (IPX203) in people with advanced disease symptoms, including possible improvements in daily activities and quality of life. The presentations began Sunday and run…
Dancing helps prevent Parkinson’s disease, obesity, dementia, depression and anxiety, says Dr. Patricia Bragg, CEO of organic health company Bragg Live Food Products. “New studies show that dancing increases your memory and helps prevent a wide variety of diseases such as Alzheimer’s,” Bragg said in a press release.
Adamas Pharmaceuticals will make two presentations in Boston this month on ADS-5102 as a treatment for involuntary muscle movements associated with Parkinson’s disease. ADS-5102, a high-dose amantadine therapy, decreases the duration, intensity and debility of the muscle movements, clinical trials have shown. The problems, which range from slight hand tremors to uncontrollable upper…
Get regular updates to your inbox.
